Bruker Daltonics and Bruker AXS to Introduce Various Innovative Solutions and Products at Pittcon 2004, Including Proteomics RIMS.Business Editors/Health/Medical Writers Pittcon 2004 BILLERICA, Mass.--(BUSINESS WIRE)--March 1, 2004 Companies Will Host Annual Press Conference and Booth Tour Bruker BioSciences Corporation Bruker Biosciences Corporation is a Massachusetts-based company formed in 2003 which develops and manufactures scientific instrumentation for academic research and industrial use. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BRKR BRKR Breaker ) today announced that its operating subsidiaries, Bruker Daltonics Inc. and Bruker AXS Inc., will introduce several innovative solutions and products for life science and materials research applications at the 2004 Pittcon Conference next week in Chicago. As a joint solution offering resulting from synergistic research and development efforts after the merger of the two companies in July 2003, both companies together will introduce a unique Proteomics RIMS(TM) (Research Information Management System). This new Proteomics RIMS bioinformatics solution will for the first time combine and integrate the data, information and knowledge generated in the proteomics research workflow from complementary mass spectrometry and x-ray crystallography technologies. Proteomics RIMS will also provide access to proteomic interaction and structural data and information provided by NMR NMR: see magnetic resonance. (in collaboration with Bruker BioSpin). Detailed press releases on Proteomics RIMS, as well as on other significant product introductions, will be released on Monday, March 8, 2004 at 7 a.m. EST EST electroshock therapy. EST abbr. electroshock therapy . Bruker Daltonics and Bruker AXS will host their annual Pittcon press conference luncheon on new product releases on Tuesday, March 9, 2004 from 12:00 noon to 1:15 p.m. Central Time at the nearby Hyatt Regency Hotel, rooms C & D. Journalists and editors are invited to RSVP (ReSerVation Protocol) A communications protocol that signals a router to reserve bandwidth for real time transmission. RSVP is designed to clear a path for audio and video traffic, eliminating annoying skips and hesitations. to brenda.prost prost interj. Variant of prosit. @bruker.com. The companies also will host their annual booth tour of new product introductions for the trade press and financial analysts at booths 4241a-b on Monday, March 8, 2004 at 10:15 a.m. Central Time. The booth tour is expected to last 45 minutes. To participate, please RSVP to michael.willett@bruker.com. ABOUT BRUKER BIOSCIENCES Bruker BioSciences, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. For more information about Bruker BioSciences Corporation, please visit www.bruker-biosciences.com. CAUTIONARY STATEMENT OF BRUKER BIOSCIENCES Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the companies' reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the companies' products, changes in governmental regulations, capital spending and government funding policies, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. . These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2002, our most recent quarterly reports on Form 10-Q, our current reports on Form 8-K and the joint proxy statement/prospectus filed in connection with the merger. We disclaim any intent or obligation to update these forward-looking statements. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion